{
}
UBS has rated Pernod Ricard as 'Neutral' with a target price of 138 euros. The company leads in premium and prestige spirits and wines, with net sales primarily from international brands (61.8%), local brands (18.2%), craft spirits (7.3%), and strategic wines (3.6%). Geographically, sales are distributed across Europe (28.3%), America (28.8%), and other regions (42.9%), supported by 94 production sites worldwide.
UBS has upgraded Sanofi to a 'Buy' rating with a target price of 110 euros, citing the neurodermatitis drug Dupixent as a key growth driver for the company in the third quarter. Analyst Carl Walton anticipates that growth will accelerate further in 2025.
UBS has upgraded its rating for Sanofi to "Buy," setting a target price of 110 euros. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the company in the third quarter, with acceleration anticipated in 2025.
UBS has lowered its target price for Nestlé S.A. to 83 francs, maintaining a 'Neutral' rating. Nestlé, the world's largest food group, generates sales across various sectors, including beverages (26.7%), pet food (20.3%), and pharmaceutical products (16.4%), with significant market presence in the USA and Canada (35%).
UBS has maintained a "Neutral" rating for Pernod Ricard, setting a target price of 138 euros. Analyst Sanjeet Aujla noted that the sales outlook for the spirits supplier remains challenging, although efforts to stabilize margins are viewed positively. Currently, the share valuation is slightly below average.
UBS has maintained a "Buy" rating for Sanofi, setting a price target of 110 euros ahead of the company's upcoming financial results. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the pharmaceutical firm in the third quarter, with acceleration anticipated in 2025.
EssilorLuxottica reported third-quarter sales of 6,437 million euros, falling 2% short of forecasts, with constant exchange rate growth at 4.0%. UBS maintains a Buy rating with a price target of 232 euros, suggesting that the promising start to the quarter may bolster the share price despite concerns over margin expansion in the second half of 2024. Investors may find reassurance in fourth-quarter forecasts amid a challenging environment.
EssilorLuxottica reported third-quarter 2024 sales of 6,437 million euros, falling 2% short of expectations. UBS maintains a Buy rating with a price target of 232 euros, noting that while growth at constant exchange rates was 4.0%, it raises concerns about margin expansion for the second half of the year. Investors may find fourth-quarter forecasts reassuring despite the challenging environment.
UBS maintains a "Buy" rating for EssilorLuxottica following its quarterly results, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has no involvement in the analysis preparation and holds no conflicts of interest regarding the investment recommendations provided.
The 2024 Paris Motor Show highlights the electric vehicle and SUV trends amid a challenging economic landscape, with significant participation from brands like Renault, which showcases the electric Renault 5 and 4. Chinese manufacturers, including Leapmotor, make a measured debut, while established European automakers like Volkswagen and BMW return to reconnect with consumers. The event reflects a market grappling with slow sales growth and a notable decline in electric vehicle demand.
FRA
Country
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs rates pernod ricard neutral with target price of 138 euros
11:58 18.10.2024
ubs upgrades sanofi to buy with target price of 110 euros
11:57 18.10.2024
ubs upgrades sanofi to buy with target price of 110 euros
11:57 18.10.2024
ubs lowers nestle target price to 83 francs maintaining neutral rating
11:13 18.10.2024
UBS maintains neutral rating for Pernod Ricard with target price of 138 euros
11:10 18.10.2024
UBS maintains buy rating for Sanofi with price target of 110 euros
11:09 18.10.2024
ubs maintains buy rating on essilorluxottica after third quarter results
10:56 18.10.2024
ubs maintains buy rating on essilorluxottica after third quarter results
10:56 18.10.2024
EssilorLuxottica receives Buy rating from UBS after quarterly results
10:50 18.10.2024
paris motor show 2024 highlights electric vehicles and suv trends
United States Dollar
Euro
AUDI AG
Zhejiang Leapmotor Technology Co., Ltd.
Mini Acorns Ltd.
XPeng Inc.
Alfa Romeo
BMW Bank GmbH
Peugeot
Chengdu Hongqi Chain Co.,Ltd.
Alpine 3V
Cadillac Building Inc.
Kia
Dacia SCI
Skyworth Digital Co., Ltd.
Stellantis N.V.
BYD Co. Ltd.
Volkswagen AG
Citroen
Ford Motor Company
Renault SA
FRA
DEU
CHN
Luca de Meo
Jérôme Marchon
Show more
09:24 18.10.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Finance Mergers & Acquisitions
Global Financial Events
CEO Changes
Retail and Consumer Goods
Banking Regulations
Market Analysis and Predictions
Industry Mergers & Acquisitions
Global Trade Developments
Energy Sector Developments
Startups & Entrepreneurship
Government Policies
Supply Chain Management
Domestic Politics
Financial Scams and Security
Government Economic Policies
Central Bank Actions
Hedge Funds & Private Equity
Countries:
Companies:
Tesla, Inc.
Barclays PLC
JPMorgan Chase & Co.
Apple Inc.
BNP Paribas SA
UBS Group AG
NVIDIA Corporation
Morgan Stanley
Bank of America Corporation
Capital One Financial Corporation
The Goldman Sachs Group, Inc.
Deutsche Bank RV Global PP
Amazon.com, Inc.
Citigroup Inc.
Commerzbank AG
SpaceXCoin USD
Credit Suisse Real Estate Fund Siat
Wells Fargo & Company
UniCredit S.p.A.
Microsoft Corporation
Currencies:
United States Dollar
Euro
Chinese Yuan
Indian Rupee
Swiss Franc
British Pound Sterling
Vietnamese Đồng
Hong Kong Dollar
Australian Dollar
United Arab Emirates Dirham
Singapore Dollar
South Korean Won
Thai Baht
Norwegian Krone
Danish Krone
Swedish Krona
Russian Ruble
Ghanaian Cedi
Canadian Dollar
Turkish Lira
People: